Intrauterine growth restriction. Maternal care for other known or suspected poor fetal growth, unspecified trimester, not applicable or unspecified
Conditions
Interventions
Intervention 1: Intervention group: mothers will take L-arginine tablets daily with a dose of 3 grams for 21 days. Intervention 2: Control group:mothers will receive daily placebo for 21 days in the f
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Diagnosis of IUGR in mothers using ultrasound and biometry
Exclusion criteria
Exclusion criteria: Medical illness such as diabetes, chronic kidney failure, heart disease, severe anemia Pregnant women with preeclampsia Fetal abnormality Smoking History of allergy to products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Doppler sonography. Timepoint: Doppler ultrasound of every two weeks until delivery. Method of measurement: ultrasound.;Sono biometric examination. Timepoint: Sonobiometry of every two weeks until delivery. Method of measurement: Sonography.;Examining complications of thenewborn. Timepoint: Examining newborn complications at birth. Method of measurement: Examining complications of the baby using blood tests and expert examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Baby's birth weightApgar scoreNICU admission ratePresence of respiratory distress syndromePresence of intracranial bleedingGestational ageCa, FBS, IGF1 and ALP blood factors of the newbornInfant mortality rateFBS mother. Timepoint: All variables are checked at the time of delivery of the mother and the birth of the baby. Method of measurement: Using blood tests and gynecologist examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Shaghayegh Moradi Alamdarloo
Shiraz University of Medical Sciences
Outcome results
None listed